Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Izanne Roos

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
European Journal of Neurology|December 12, 2023
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort studyCarmela Sales, Mary Ann Anderson, Valeriya Kuznetsova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 8, 2026
Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohortsLaura Hogenboom, Antonia McLean, Lisa Schoof, et al.
Epilepsy Research|November 10, 2019
Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizuresAlbert D Wang, Michelle Leong, Benjamin Johnstone, et al.
Seizure|October 27, 2019
Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizuresMichelle Leong, Albert D Wang, David Trainor, et al.
Multiple Sclerosis and Related Disorders|June 6, 2022
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemicVivien Li, Izanne Roos, Mastura Monif, et al.
Expert Review of Hematology|August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapyValeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Brain and Behavior|April 30, 2024
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosisJannis Müller, Izanne Roos, Tomas Kalincik, et al.
BMJ Neurology Open|September 19, 2024
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective studyValeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
Clinical Drug Investigation|March 18, 2022
Multiple Sclerosis Relapses Following Cessation of FingolimodCharles B Malpas, Izanne Roos, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2026
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, CanadaNathan Y Chu, Jodie I Roberts, David J Hunt, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
European Journal of Neurology|December 12, 2023
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort studyCarmela Sales, Mary Ann Anderson, Valeriya Kuznetsova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 8, 2026
Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohortsLaura Hogenboom, Antonia McLean, Lisa Schoof, et al.
Epilepsy Research|November 10, 2019
Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizuresAlbert D Wang, Michelle Leong, Benjamin Johnstone, et al.
Seizure|October 27, 2019
Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizuresMichelle Leong, Albert D Wang, David Trainor, et al.
Multiple Sclerosis and Related Disorders|June 6, 2022
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemicVivien Li, Izanne Roos, Mastura Monif, et al.
Expert Review of Hematology|August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapyValeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Brain and Behavior|April 30, 2024
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosisJannis Müller, Izanne Roos, Tomas Kalincik, et al.
BMJ Neurology Open|September 19, 2024
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective studyValeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
Clinical Drug Investigation|March 18, 2022
Multiple Sclerosis Relapses Following Cessation of FingolimodCharles B Malpas, Izanne Roos, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2026
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, CanadaNathan Y Chu, Jodie I Roberts, David J Hunt, et al.
Pageof 8